Ginkgo Bioworks Holdings Inc at UBS Genomics 2.0 and MedTech Innovations Summit Transcript
All right, guys. Thanks so much for joining. We are starting now our Innovation Across Drug Discovery, Molecule Synthesis, & Precision Medicine. So we've thrown everything that we possibly can at the title. Hopefully, we've encapsulated enough.
But I'm Liza Garcia, UBS life science tools and diagnostics analyst. I'm being joined by my co-coverage, John Sourbeer. And then we have Sean McClain, the CEO of Absci. We have Patrick Finn, the Chief Operating Officer and President of Twist. We have Anne-Marie Wagner, SVP, Corporate Development at Ginkgo, and we have Ross Muken here as well, the CFO of SOPHiA GENETICS. And so we have quite a number of companies to take it off. And I think we'll start on some broader themes and then we'll drill down to the company-level questions.
But just to start it off, obviously, maybe we'll go down the row from Ross, left to right. But -- all right. So a broad one to start. So just thinking about utilization of data and new technologies to better deliver on
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |